

## Supplementary Material

10.1302/0301-620X.106B4.BJJ-2023-0904.R1

**Table i.** Patients receiving and returning patient-reported outcome measures at four, 12, and 36 months' follow-up.

Demographic	No. of patients		Time of follow-up															
			4 months				12 months				36 months							
	n, total	n, THA	Sent		Response*		p-value†	Sent		Response*		p-value†	Sent		Response*		p-value†	
n			%	n	%	n		%	n	%	n		%	n	%			
<b>Sex</b>																		
Female	23,649	1,100	20,492	87	11,837	58	0.478	17,573	74	10,309	59	0.737	12,878	54	6,975	54	0.023	
Male	11,557	594	9,340	81	5,436	58		7,770	67	4,578	59		5,478	47	3,064	56		
<b>Age (yrs)</b>																		
< 65	3,461	561	3,355	97	1,983	59	< 0.001	2,757	80	1,579	57	< 0.001	2,494	72	1,365	55	< 0.001	
65 to 74	5,828	765	5,507	94	3,585	65		4,498	77	2,884	64		3,755	64	2,296	61		
75 to 79	4,637	182	4,126	89	2,573	62		3,667	79	2,365	64		2,874	62	1,734	60		
80 to 84	6,417	112	5,460	85	3,145	58		4,810	75	2,873	60		3,531	55	1,962	56		
85 to 89	7,680	57	6,208	81	3,401	55		5,387	70	3,017	56		3,477	45	1,721	49		
> 90	7,183	17	5,176	72	2,587	50		4,224	59	2,169	51		2,225	31	961	43		
<b>ASA<sup>1</sup></b>																		
1	1,312	207	1,308	100	958	73	< 0.001	1,116	85	796	71	< 0.001	1,055	80	706	67	< 0.001	
2	11,696	1,010	11,047	94	7,145	65		9,598	82	6,207	65		7,967	68	4,771	60		
3	19,420	456	15,911	82	8,441	53		13,493	69	7,334	54		8,791	45	4,335	49		
4	2,735	21	1,550	57	721	47		1,125	41	547	49		538	20	226	42		

5	53	0	16	30	8	50		11	21	3	27		5	9	1	20	
<b>CCI<sup>2</sup></b>																	
0	24,200	1,350	21,179	88	12,587	59	< 0.001	18,217	75	10,917	60	< 0.001	13,791	57	7,665	56	< 0.001
1 to 2	7,775	268	6,404	82	3,486	54		5,390	69	3,027	56		3,596	46	1,870	52	
3 to 4	2,053	45	1,533	75	817	53		1,231	60	664	54		713	35	365	51	
5+	1,178	31	716	61	383	53		506	43	279	55		256	22	139	54	
<b>Cognitive impairment</b>																	
0	26,810	1,691	24,030	90	15,141	63	< 0.001	20,832	78	13,280	64	< 0.001	16,126	60	9,397	58	< 0.001
1	8,396	3	5,802	69	2,132	37		4,511	54	1,607	36		2,230	27	642	29	
<b>Residential status</b>																	
Home	31,603	1,661	27,371	87	16,364	60	< 0.001	23,516	74	14,206	60	< 0.001	17,486	55	9786	56	< 0.001
HCF	3,561	21	2,423	68	898	37		1,824	51	668	37		847	24	245	29	
<b>Household income (quartile)</b>																	
1	8,791	182	7,078	81	3,465	49	< 0.001	5,994	68	3,039	51	< 0.001	3,892	44	1,777	46	< 0.001
2	8,793	303	7,305	83	3,829	52		6,136	70	3,330	54		4,275	49	2,093	49	
3	8,789	379	7,439	85	4,545	61		6,417	73	3,950	62		4,684	53	2,665	57	
4	8,791	818	7,972	91	5,423	68		6,758	77	4,555	67		5,482	62	3,496	64	
<b>Educational level</b>																	
Primary	15,065	543	12,495	83	6,612	53	< 0.001	10,607	70	5,774	54	< 0.001	7,394	49	3,600	49	< 0.001
Secondary	15,342	801	13,092	85	7,864	60		11,147	73	6,719	60		8,174	53	4,680	57	
Tertiary	4,799	350	4,245	88	2,797	66		3,589	75	2,394	67		2,788	58	1,759	63	

Percentages in each column represent the proportion of patients who received and returned the forms after four, 12, and 36 months.

\*Response denotes the number of returned patient-reported outcome measures (PROMs) and the response rate in the defined categories.

†Pearson's chi-squared test.

ASA, American Society of Anesthesiologists; CCI, Charlson Comorbidity Index; HCF, healthcare facility; Response, number of returned patient-reported outcome measure (PROM) questionnaires; Sent, number of sent PROM questionnaires; THA, total hip arthroplasty (not included at 12 and 36 months' follow-up).

## References

1. **Saklad M.** Grading of patients for surgical procedures. *Anesthesiology*. 1941;2(3):281–284.
2. **Charlson ME, Pompei P, Ales KL, MacKenzie CR.** A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373–383.